NCT02388347View on ClinicalTrials.gov

A Study to Assess the Safety of MEDI7836 in Healthy Adults.

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

April 30, 2016

Conditions
Healthy Adults
Interventions
DRUG

Placebo SC

Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.

BIOLOGICAL

MEDI7836 Dose 1

Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.

BIOLOGICAL

MEDI7836 Dose 2

Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.

BIOLOGICAL

MEDI7836 Dose 3

Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.

BIOLOGICAL

MEDI7836 Dose 4

Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY